Back to News
Market Impact: 0.2
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
Source: GlobeNewswire
Healthcare & BiotechTechnology & Innovation
Tempest said the transaction complements its CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform. The company plans to bring the platform into clinical testing later this year, representing a modest positive development for its cell-therapy pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
TPST0.35
More News
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Wall Street Punishes Tech Stocks on Earnings Misses
- Reddit stock plunges 30% after weak outlook, heads for worst day ever
- Canada expects to seal a deal in June to become the EU’s first ‘associate member’ — ‘everything short of full EU membership’
- Are Houthis using Russian satellites as Saudi Arabia fends off strikes?
- Tech sell-off drives US markets down by nearly $1tn after subpar earnings reports